Pharma News

Sandoz US acquisition of ranibizumab biosimilar from Coherus

Home/Pharma News | Posted 09/02/2024

On 22 January 2024, it was announced that in the US, Sandoz will acquire ranibizumab biosimilar Cimerli (ranibizumab) from Coherus BioSciences.

Fiocruz and Pfizer sign agreement for generic of Xeljanz

Home/Pharma News | Posted 30/01/2024

Farmanguinhos/Fiocruz, the Institute of Drug Technology in Brazil, has signed a technology transfer agreement with Pfizer Brazil for the manufacturing of tofacitinib citrate, a generic counterpart to Xeljanz.

Biocon to commercialize biosimilars in 31 European countries

Home/Pharma News | Posted 23/01/2024

Biocon Biologics has successfully integrated Viatris’ biosimilars business in 31 European countries, it was announced in late November 2023.

Genfar: Eurofarma's new generic brand in Latin America

Home/Pharma News | Posted 12/12/2023

Eurofarma announced on 29 September 2023 that it completed the acquisition of Laboratorios Genfar. Genfar is a generic drug company owned by the French company Sanofi, with offices in Colombia, Ecuador, and Peru.

Phase III trial results of CinnaGen’s ocrelizumab similar biotherapeutic product

Home/Pharma News | Posted 28/11/2023

Ocrelizumab is a therapeutic monoclonal antibody (mAb) that represents a different scientific approach to treating multiple sclerosis (MS). It is a humanized anti-CD20 mAb that targets CD20 marker on B lymphocytes, a typo of immune cell that plays a key role in the disease and serves as an immunosuppressive drug. Ocrelizumab binds selectively to CD20, which is expressed on the membrane of B cells. When ocrelizumab binds to CD20 on B cells, these cells are eliminated by antibody-dependent cell-mediated cytotoxicity and, to a lesser extent, complement-dependent cytotoxicity.

Insulin biosimilars: new CRL for Biocon, new deal for Meitheal/Tonghua Dongbao

Home/Pharma News | Posted 21/11/2023

In a dynamic landscape of pharmaceutical developments, Biocon Biologics (Biocon) faces a regulatory hurdle with a complete response letter from the US Food and Drug Administration (FDA), while Meitheal Pharmaceuticals expands its reach through a strategic licensing agreement with Tonghua Dongbao Pharmaceutical.

Abbott and mAbxience partnership for biosimilars in emerging markets

Home/Pharma News | Posted 14/11/2023

Abbott and mAbxience announced on 20 September 2023 that they had entered into a strategic partnership to commercialize several biosimilars in Latin America and other emerging markets.

Fresenius Kabi and Formycon reach agreement with J&J, Alvotech and Teva expand partnership

Home/Pharma News | Posted 08/09/2023

In August 2023, Fresenius Kabi and Formycon announced that they have entered into a settlement agreement with Johnson & Johnson (J&J) concerning FYB202, a proposed ustekinumab biosimilar in the US. This followed the late July 2023 news that Alvotech and Teva Pharmaceuticals (Teva) have agreed to expand their existing strategic partnership agreement.

Cuba and China strengthen ties in biotechnology

Home/Pharma News | Posted 01/09/2023

The biotechnological cooperation between Cuba and China has been a longstanding relationship in the scientific and technological realms. For the benefit of both countries, Havana and Beijing have undertaken various collaborations in the field of biotechnology, driven by their bilateral relations and shared interest in the development of the healthcare and pharmaceutical industry.

New BioFactura-CuraTeQ partnership for ustekinumab biosimilar

Home/Pharma News | Posted 25/08/2023

CuraTeQ Biologics Private Limited, a subsidiary of India’s Aurobindo Pharma Limited, has entered into an exclusive license agreement to commercialize BFI-751, BioFactura’s proposed biosimilar to Stelara (ustekinumab).